1.The Clinical Observation on Treatment of Stable Cardiac Angina Pectoris due to Qi-deficiency and Blood-stasis with Yiqi Huoxue Jiedu Decoction
Shugen DING ; Zhongzhi LI ; Qianglong XIE ; Yebin HU
International Journal of Traditional Chinese Medicine 2008;30(4):268-269
Objective To investigate the effects of Yiqi Huoxue Jiedu Decoction on Syndrome,hemorheology and homocysteine(Hcy)of patients with stable cardiac angina pectoris due to qi-deficiency and blood-stasis.Methods 98 patients with stable angina pectoris due to qi-deficiency and blood-stasis are randomly divided into a treatment group and a control groups.Conventional treatments as inhaling oxygen,dilating coronary artery,and resisting coagulation were used for the both group.Besides conventional treatments.Yiqi Huoxue Jiedu Decoction was additionally given to the treatment group.Observe the changes of Syndrome,hcmorheology and homocysteine.Results The improvement of Syndrome,hemorheology and homocysteine in the treatment group was significantly better than the Control group(P<0.01 or P<0.05).Conclusion The curative effect of treating stable a.gina pectoris due to qi-deficiency and blood-stasis with conventional treatments together with Yiqi Huoxue Jiedu Decoction is better than conventional western medical treatment.
2.Effects of RNA interference of targeting Cyclin D1 gene on hepatoma cell proliferation and Mdm2 gene expression
Hongying ZHANG ; Shugen HU ; Lilin HU ; Hao DING
Chongqing Medicine 2018;47(15):1981-1985
Objective To investigate the effects of down-regulating Cyclin D1 expression on Mdm2 gene expression and proliferation of human hepatoma cells.Methods Cyclin D1-siRNA was transfected into the hu man hepatoma cell line Hep3B s with liposome.The experiment was divided into the blank control group,negative control siRNA (NC-siRNA) group and Cyclin D1-siRNA group.RT-PCR and Western blot were used to detect the expressions of Cyclin D1,Mdm2,Mdm4,P53 and P21.The cell cycle was measured by flow cytometer;the cellular activity was tested with MTT;the cell apoptosis was examined by TUNEL.Results Compared with the blank control group and NC-siRNA group,the expressions of P53 and P21 in the Cyclin D1-siRNA group were increased (P<0.05),while the expressions of Cyclin D1,Mdm2 and Mdm4 were decreased (P<0.01);there were no significant differences in the G1,S and G2 phases among 3 groups(P>0.05);the cell vitality in the in the Cyclin D1-siRNA group was significantly weakened compared with the other two groups(P<0.01),while the cell apoptosis was significantly enhanced(P<0.01).Conclusion The down-regulation of Cyclin D1 gene expression could inhibit the expressions of Mdm2 and Mdm4,and up-regulates the expressions of P53 and P21.Down-regulating Cyclin D1 expression can inhibit the proliferation of liver cancer cells and promotes their apoptosis.
3.Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension
Huisheng CHEN ; Yi YANG ; Jun NI ; Guofang CHEN ; Yong JI ; Fei YI ; Zhuobo ZHANG ; Jin WU ; Xueli CAI ; Bei SHAO ; Jianfeng WANG ; Yafang LIU ; Deqin GENG ; Xinhui QU ; Xiaohong LI ; Yan WEI ; Shugen HAN ; Runxiu ZHU ; Jianping DING ; Hua LYU ; Yining HUANG ; Yonghua HUANG ; Bo XIAO ; Tao GONG ; Xiaofei YU ; Liying CUI
Chinese Journal of Internal Medicine 2022;61(8):916-920
Objective:To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection.Methods:This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke: a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate or control, which were assessed during the treatment period (14 days), and the proportion of the patients with normal blood pressure was analyzed after the treatment period. Furthermore, a subgroup analysis was performed to investigate a possible effect of the history of hypertension on outcomes.Results:This analysis included 809 patients with hypertension. There was no significant difference in patients blood pressure and the proportion of patients with normal blood pressure (60.5% vs. 59.0%, P>0.05) between cinepazide maleate group and control group. Conclusion:Administration of cinepazide maleate injection does not affect the management of clinical blood pressure in patients with AIS.